Global Cervical Cancer Diagnostic Market Expected to Reach XX Million by 2025
According to new report published by Reports Monitor “Cervical Cancer Diagnostic Market By Test, Screening Method, Therapy, Age Group & End-User: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the Cervical Cancer Diagnostic Market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. North America dominates the Cervical Cancer Diagnostic Market, and is anticipated to grow continuously throughout the forecast period.
Cervical cancer indicates the anomaly of the cervical cells found in cervix. Abnormal growth of the glandular cells and squamous cells results into Adenocarcinoma and Squamous cell carcinoma respectively and sometimes mixture of both called as Adnosquamous carcinoma. Abnormal vaginal bleeding, pain during sexual intercourse and unusual vaginal discharge are some of the symptoms for cervical cancer.
Human Papilloma Virus infection is the major cause of cervical cell malignancy. In addition weakened immune system, conception preventive pills, smoking habits, unprotected and early age intercourse and growing stoutness among population causes the incidences of cervical cancer driving the market growth for cervical cancer diagnostic. Nonetheless, soaring cost of the cancer treatment and stringent guidelines for cervical cancer screening might hinder the growth of the market.
Pap test accounts for highest share of the market in terms of volume as the test aids in recognizing aberrant cells that have potential to develop into cancerous cell in later stage. Also efficiency and awareness associated with the early diagnosis supports the growth of this segment. However, HVP testing market is presumed to witness speedy growth owing to technological development in diagnostic procedures at low cost and use of biomarkers in screening techniques.
Key Findings and Scope • In the year 2016, Pap test held larger share of 49.6% of the market. Whereas market for HPV test is anticipated to grow at CAGR of 15.3 %. • By age group the market for 40 above age group is expected to grow at CAGR of 5.69 during the forecast period of 2017-2025. • Geographically, North America dominates the market for cervical cancer diagnostic owing to increased prevalence of HVP infection, growing number of smokers and rising geriatric and obese population. • Emerging economies like China and Japan in Asia-Pacific are predicted to grow lucratively with the CAGR of 9.6% over the forecast period. Prominent vendors mentioned in the report are Abbott Molecular, F. Hoffmann-La Roche Ltd, QIAGEN, Quest Diagnostics, Inc., Hologic, Inc., Arbor Vita Corporation, OncoHealth Corporation, Dell Guided Therapeutics, Inc., CooperSurgical, Inc., and Becton, Dickinson and Company.
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.